# To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV

> **NCT04054492** · PHASE4 · COMPLETED · sponsor: **China National Biotec Group Company Limited** · enrollment: 604 (actual)

## Conditions studied

- Vaccination
- Reaction - Vaccine

## Interventions

- **BIOLOGICAL:** Sabin-IPV+bOPV+bOPV
- **BIOLOGICAL:** Sabin-IPV+Sabin-IPV+bOPV
- **BIOLOGICAL:** Sabin-IPV+Sabin-IPV+Sabin-IPV

## Key facts

- **NCT ID:** NCT04054492
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2019-01-25
- **Final completion:** 2019-06-12
- **Target enrollment:** 604 (ACTUAL)
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054492, "To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04054492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*